Magnetic Nanoparticles for the Delivery of Dapagliflozin to Hypoxic Tumors: Physicochemical Characterization and Cell Studies
- 315 Downloads
In solid tumors, hypoxia (lack of oxygen) is developed, which leads to the development of resistance of tumor cells to chemotherapy and radiotherapy through various mechanisms. Nevertheless, hypoxic cells are particularly vulnerable when glycolysis is inhibited. For this reason, in this study, the development of magnetically targetable nanocarriers of the sodium-glucose transporter protein (SGLT2) inhibitor dapagliflozin (DAPA) was developed for the selective delivery of DAPA in tumors. This nanomedicine in combination with radiotherapy or chemotherapy should be useful for effective treatment of hypoxic tumors. The magnetic nanoparticles consisted of a magnetic iron oxide core and a poly(methacrylic acid)-graft-poly(ethyleneglycol methacrylate) (PMAA-g-PEGMA) polymeric shell. The drug (dapagliflozin) molecules were conjugated on the surface of these nanoparticles via in vivo hydrolysable ester bonds. The nanoparticles had an average size of ~ 70 nm and exhibited a DAPA loading capacity 10.75% (w/w) for a theoretical loading 21.68% (w/w). The magnetic responsiveness of the nanoparticles was confirmed with magnetophoresis experiments. The dapagliflozin-loaded magnetic nanoparticles exhibited excellent colloidal stability in aqueous and biological media. Minimal (less than 15% in 24 h) drug release from the nanoparticles occurred in physiological pH 7.4; however, drug release was significantly accelerated in pH 5.5. Drug release was also accelerated (triggered) under the influence of an alternating magnetic field. The DAPA-loaded nanoparticles exhibited higher in vitro anticancer activity (cytotoxicity) against A549 human lung cancer cells than free DAPA. The application of an external magnetic field gradient increased the uptake of nanoparticles by cells, leading to increased cytotoxicity. The results justify further in vivo studies of the suitability of DAPA-loaded magnetic nanoparticles for the treatment of hypoxic tumors.
KEY WORDSdapagliflozin magnetic nanoparticles hypoxia tumor drug targeting cytotoxicity
This research was supported by the “ΙΚΥ FELLOWSHIPS OF EXCELLENCE FOR POSTGRADUATE STUDIES IN GREECE – SIEMENS PROGRAM”. The authors would like to thank the Advanced Light Microscopy facility of the Department of Physiology, School of Medicine, University of Patras, especially Dr. Argiro Kalogeropoulou, and Professor Stavros Taraviras, for their help with the confocal microscopy.
- 1.Szablewski L. Expression of glucose transporters in cancers. Biochim Biophys Acta. 1835;2013:164–9.Google Scholar
- 7.Obermeier MT, Yao M, Khanna A, Koplowitz B, Zhu M, Li W, et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose Cotransporter type II inhibitor, in animals and humans. Am Soc Pharmacol Exp Ther ASPET. 2009;38:405–14.Google Scholar
- 12.Chen EY, Samkoe KS, Hodge S, Tai K, Hou H, Petryk AA, et al. Chapter 12 modulation of hypoxia by magnetic nanoparticle hyperthermia to augment therapeutic index. In: Swartz HM, et al., editors. Oxygen Transport to Tissue XXXVI, Advances in Experimental Medicine and Biology; 2014. pp. 87–95, 2014812.Google Scholar
- 32.Australian Government, Department of Health and Ageing. Australian public assessment report for dapagliflozin propanediol monohydrate. Bristol-Myers Squibb Australia Pty: Ltd/AstraZeneca Pty Ltd.; 2013.Google Scholar
- 33.Tas AC. Use of biomineralization media in biomimetic synthesis of hard tissue substitutes. In: McKittrick JM, Narayan R, editors. Advances in bioceramics and biotechnologies II. USA: Wiley; 2014. p. 92.Google Scholar
- 36.Steinberg G, Tsakiridis T, Villani L. International application published under the patent cooperation treaty (PCT). International publication number WO 2016/134486 A1, agent: Bereskin & Parr LLP/S.E.N.C.R.L., S.R.L., Toronto.Google Scholar
- 47.Kato Y, Ozawa S, Miyamoto C, Maehata Y, Suzuki A, Maeda T, et al. Acidic extracellular microenvironment and cancer. Cancer Cell Int. 2013;13(89):1–8.Google Scholar
- 48.Kong SD, Zhang W, Lee JH, Choi C, Khamwannah J, Karin M, et al. Externally triggered on-demand drug release and deep tumor penetration. J Vac Sci Technol B Nanotechnol Microelectron Mater Process Meas Phenom. 2012;30(2):02C102.Google Scholar
- 51.Villani LA, Smith BK, Marcinko K, Ford RJ, Broadfield LA, Green AE, et al. The diabetes medication canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration. Mol Ther. 2016;5:1048–56.Google Scholar
- 52.Xu HL, Mao KL, Huang YP, Yang JJ, Xu J, Chen PP, et al. Glioma-targeted superparamagnetic iron oxide nanoparticles as drug-carrying vehicles for theranostic effects. Nano. 2016;8:14222–36.Google Scholar